Location Directory

Clinical trials in Seattle, Washington

This page shows live ClinicalTrials.gov search results for Seattle, Washington, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

11419

Shown on this page

Current sort

Institutions in Seattle

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Fred Hutchinson Cancer Center

Live official records

Open in full search

Conditions: Ischemic Stroke
Interventions: TS23; Biological
Lead sponsor: Translational Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Interventions: Tovorafenib, Chemotherapeutic Agent; Drug
Lead sponsor: Day One Biopharmaceuticals, Inc.; Industry
Eligibility: Up to 25 Years
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more

Conditions: Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions: Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo; Drug · Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Years to 28 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Tobacco-Related Carcinoma
Interventions: Smartphone app-based Intervention, Communication intervention, Survey Administration, Interview, Assessment; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Las Cruces, New Mexico • Seattle, Washington

Conditions: Gastrointestinal Stromal Tumors
Interventions: Ripretinib, Sunitinib; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 43
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 38 more

Conditions: Autism Spectrum Disorder
Interventions: Brush Up App, Brush Down App; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 8 Years to 17 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Graft vs Host Disease
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 99 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 15
States / cities: Phoenix, Arizona • Duarte, California • Aurora, Colorado + 11 more

Conditions: Type 1 Diabetes, New Onset
Interventions: Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 9 Years to 20 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Acute Pancreatitis
Interventions: CyTOF Analysis; Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Columbus, Ohio + 2 more

Conditions: Generalized Myasthenia Gravis
Interventions: zilucoplan (RA101495); Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 33
States / cities: Mobile, Alabama • Phoenix, Arizona • Irvine, California + 29 more

Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Interventions: Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, Leucovorin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 93
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 81 more

Conditions: Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
Interventions: AVZO-1418, Combination Agent 1, Combination Agent 2; Drug
Lead sponsor: Avenzo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 19
States / cities: Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more

Clinical trials in Seattle, Washington

Filter and sort this location

Institutions in Seattle

Live official records

Strategy for Improving Stroke Treatment Response

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

A Novel Mobile Health Intervention for Improving Tobacco Cessation Among Young Adults

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Mobile App-Based Intervention to Improve Toothbrushing in Children and Teens With Autism

Pediatric cGVHD Symptom Scale

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

iMmune SignAtures and Clinical outComes in AP

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)